Enter multiple symbols separated by commas

AstraZeneca Fourth-Quarter Profit Up

AstraZeneca, Europe’s fourth-largest drug maker by prescription drug sales, posted a 21% rise in fourth-quarter earnings per share, compared to the last-year quarter.

AstraZeneca earned 93 cents a share in the last three months of 2006, compared with 77 cents a share in the year-ago quarter. But that was a penny below the Thomson Financial consensus estimate of 94 cents a share.

Sales in the company rose 11% for the fourth-quarter with $7.2 billion compared to $6.3 billion for the same period last year. The full-year sales for 2006 came in at $26.5 billion. That was a little better than the full-year consensus of $26 billion.

Pretax profit for the company was up 29% for the fourth-quarter at $2.1 million compared to $1.6 million for the same quarter, 2005.

The gain in profit is mainly due to restructuring activities, which included cutting around 3,000 positions, and the increasing demand for the company’s key drugs which include: Nexium, a heartburn drug; Seroquel, an antipsychotic; Symbicort, a treatment for breast cancer and Crestor, a cholesterol drug.

AstraZeneca has been under increasing pressure from generic drug competition which looks set to continue this year. Focus will now turn to the company’s strategy.

Shares in the company are trading up.

For 2007 AstraZeneca expects earnings in a range of $3.80 to $4.05 per share.

Contact U.S. News


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

  • The California property that once served as Michael Jackson's home and personal fantasyland is being listed at $100 million.

  • Lottery ticket

    A thief who broke into the car of a Seattle couple left behind a million-dollar lottery ticket, NBC News reports.

  • The Lamborghini SpA Urus SUV.

    There's no shortage of luxury vehicle choices, but increasingly the wealthy are opting for high-end SUVs instead of traditional models.

U.S. Video

  • Dennis Hastert indicted

    Former U.S. House Speaker Dennis Hastert is in trouble for alleged hush money withdrawals and lying to the FBI, reports CNBC's Eamon Javers.

  • Someone has to go to jail: Kovacevich

    Former Wells Fargo CEO Richard Kovacevich, weighs in on accountability and "criminal" activity that occurred during the financial crisis, and comments made by Dick Fuld about Lehman's collapse.

  • Regulations 'killing' small banks: Kovacevich

    Former Wells Fargo CEO Richard Kovacevich, shares his thoughts on how regulations are hurting small businesses and banks.